STAMFORD, Conn., Sept. 28, 2026 /PRNewswire/ — Avesi Partners (“Avesi”) announced that it has made an investment in New Age Medical (“New Age” or the “Company”), a leading MedTech hub serving the spinal surgery market. Avesi has partnered alongside New Age’s founder and CEO, Kevin Bly, and the Company’s existing management team to support New Age’s mission of enhancing patient care and driving operational efficiency by optimizing and accelerating the flow of medical solutions from manufacturers, through reps, to hospitals, surgeons, and patients.
Avesi Partners Announces Investment in New Age Medical
3 min read Premium comments
investmentAvesi PartnersNew Age Medicalspinal surgery marketenhance patient careoperational efficiency
Headquartered in St. Louis, MO, New Age Medical sits at the intersection of medical device manufacturers, hospitals & ambulatory surgery centers (“ASCs”), surgeons, and medical device sales representatives. New Age works nationwide with 85+ original equipment manufacturers (“OEMs”), 100+ reps, 200+ hospitals/ASCs, and 350+ surgeons, ensuring leading technology is accessible to those who need it. The New Age model reduces supply chain complexity and enables vendor consolidation for hospitals and ASCs, while bringing surgeons and patients the most innovative products OEMs have to offer.
“When we founded New Age Medical in 2012, the goal was simple: make it easier for surgeons to get the right products for their patients, and easier for the manufacturers building those products to reach them,” said Kevin Bly, Founder and Chief Executive Officer of New Age Medical. “Avesi shares our conviction that durable growth is the result of doing right by every stakeholder we serve—surgeons, hospitals, manufacturers, and the reps who bring it all together. The cultural alignment between our two organizations was clear from our very first conversation, as was a shared, growth-oriented mindset. With Avesi’s commitment and resources behind us, we can extend best-in-class product access to more surgeons, more facilities, more reps and ultimately more patients across the country.”
“Avesi has targeted innovative businesses that help hospitals and health systems deliver the highest standards of care while reducing administrative burden,” said Pete Tedesco, Managing Director at Avesi. “New Age delivers this value to its stakeholders and operates in a large, growing market with substantial opportunity to expand. We look forward to pairing our resources and healthcare expertise with the talented team at New Age to continue delivering exceptional service and extend the Company’s impact across new specialties and markets.”
“New Age Medical is one of a kind in its sector given its long-term track record of growth, the strength of its relationships across surgeons, reps, OEMs, and facilities, and the differentiated value it delivers to each,” said Chris Laitala, Managing Partner at Avesi. “Our team at Avesi is excited to work alongside management in the coming years to further expand the Company’s reach and capabilities.”
About New Age Medical
New Age Medical is the MedTech hub that optimizes and accelerates the flow of medical solutions from manufacturers, through reps, to hospitals and surgeons, all with the overarching goal of enhancing patient care and driving operational efficiency. Founded in 2012 and headquartered in St. Louis, MO, New Age works with 85+ OEMs, 100+ reps, 200+ hospitals/ASCs, and 350+ surgeons nationwide, providing top-quality spinal implants, orthobiologics, and related products to ensure exceptional patient care.
For more information, visit https://newagemedical.com/ or https://www.linkedin.com/company/new-age-medical-llc/.
About Avesi Partners
Avesi Partners, with offices in Stamford, CT and Richmond, VA, and over $2.2 billion in assets under management, focuses on partnering with lower-middle market privately held and family-owned businesses in key sectors of the economy, including healthcare services and technology, and business services. Avesi seeks to provide the expertise and resources to empower businesses to attain their full vision in a time and capital efficient manner. Avesi’s goal is to collaborate with families, founders, and executives to accelerate growth and expansion while positioning the businesses to achieve long-term success and enduring value. Target platform companies typically have approximately $5-30 million of EBITDA.
For further information, visit www.avesipartners.com or www.linkedin.com/company/avesi-partners.
New Age Medical Contact
info@newagemedical.com
Avesi Contact
info@avesipartners.com
SOURCE Avesi Partners
Author
TH
TJ Halvorson
The De Angelis Group | Orthopedics This Week | MSK Innovations
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
Avesi Partners invested in New Age Medical, a MedTech hub optimizing the spinal surgery market supply chain. This strategic investment aims to enhance patient care and operational efficiency by streamlining product flow from manufacturers to hospitals and surgeons. New Age's model reduces supply chain complexity and enables vendor consolidation, offering a competitive advantage in a growing market by ensuring access to innovative medical solutions.
- New Age Medical's strategy focuses on optimizing product flow, reducing supply chain complexity, and enabling vendor consolidation for hospitals and ASCs.
- Avesi Partners targets businesses that deliver high standards of care while reducing administrative burden, aligning with New Age's value proposition in the spinal surgery market.
PhD Lens: Clinical and outcomes impact
Avesi Partners' investment in New Age Medical aims to enhance patient care by optimizing access to spinal surgery solutions. New Age Medical, a MedTech hub, facilitates the flow of medical products, including spinal implants and orthobiologics, from manufacturers to surgeons and patients. This model ensures that innovative technologies are readily available, supporting improved clinical outcomes through efficient product delivery.
- New Age Medical's core mission is to enhance patient care by optimizing and accelerating the flow of medical solutions to surgeons and hospitals.
- The company provides access to top-quality spinal implants, orthobiologics, and related products, ensuring innovative technology reaches patients.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.